We are live on ! Find out more
RM

RP Management Portfolio holdings

AUM $139M
1-Year Est. Return 37.98%
This Fund
S&P 500
This Quarter Est. Return
+95.46%
1 Year Est. Return
-37.98%
3 Year Est. Return
+207.8%
5 Year Est. Return
+1,098.05%
10 Year Est. Return
AUM
$517M
AUM Growth
+$195M
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
6
New
Increased
Reduced
Closed

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 92.24%
2 Miscellaneous 7.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
IMMU
1
DELISTED
Immunomedics Inc
IMMU
$155M 29.96%
4,373,178
BHVN
2
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$154M 29.83%
2,111,111
EPZM
3
DELISTED
Epizyme, Inc
EPZM
$147M 28.46%
9,166,667
EPZM
4
CALL
DELISTED
Epizyme, Inc
EPZM
$40.1M 7.76%
2,500,000
CYTK icon
5
Cytokinetics
CYTK
$10.8B
$20.6M 3.99%
875,656
VIRX
6
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$34K 0.01%
3,700

Similar funds

RP Management's Q2 2020 Portfolio in Review

As of Q2 2020, RP Management held 6 positions worth $517M, up 61% from $322M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q2 2020: portfolio turnover was 0%. RP Management opened no new positions and made no exits, leaving the 6-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 88% a quarter earlier, followed by Miscellaneous.

  • RP Management's ten largest holdings make up 100% of its $517M portfolio in Q2 2020.
  • RP Management opened 0 new positions and closed 0 in Q2 2020.
  • RP Management's portfolio value rose 61% quarter-over-quarter to $517M.

Based on RP Management's 13F filing for Q2 2020, filed 14 Aug 2020.